Systemic reactions associated with ophthalmic medications

Ophthalmology Clinics of North America

Volumn 18, Issue 4, 2005, Pages 569-584

  Lama, Paul J ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ACETYLCHOLINE; ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; BRIMONIDINE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; CARVEDILOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYCLOPLEGIC AGENT; DIPIVEFRINE; DORZOLAMIDE; ECOTHIOPATE IODIDE; METHAZOLAMIDE; METOPROLOL; MIOTIC AGENT; MYDRIATIC AGENT; PHENYLEPHRINE; PILOCARPINE; PROPRANOLOL; PROSTAGLANDIN DERIVATIVE; TIMOLOL; UNINDEXED DRUG;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; AGRANULOCYTOSIS; ANOREXIA; APLASTIC ANEMIA; BONE MARROW APLASIA; BONE MARROW TOXICITY; BRADYCARDIA; BRONCHOSPASM; BRONCHUS SECRETION; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; DEFECATION DISORDER; DIARRHEA; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EXPOSURE; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TRANSPORT; ERYTHROCYTE COUNT; EYE DISEASE; FASCICULATION; FATIGUE; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL HEMORRHAGE; GLAUCOMA; HEART INFARCTION; HEMODYNAMICS; HUMAN; HYPERTENSION; HYPOTENSION; HYPOTHERMIA; INTRAOCULAR HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LACRIMAL DUCT; LACRIMATION; LACTATION; LETHARGY; LEUKOPENIA; LIBIDO DISORDER; MICTURITION DISORDER; MIOSIS; MUSCLE CRAMP; MUSCLE WEAKNESS; NASOPHARYNX; NAUSEA; PARALYSIS; PARESTHESIA; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RESPIRATORY FAILURE; REVIEW; RISK BENEFIT ANALYSIS; SALIVATION; SEIZURE; SENSORY DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SWEATING; SYNCOPE; TACHYCARDIA; TERATOGENICITY; THROMBOCYTOPENIA; THYROID DISEASE; UREMIA; VOMITING;

ANIMALS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; EYE DISEASES; HUMANS; OPHTHALMIC SOLUTIONS; RISK FACTORS;

EID: 28444474850     PISSN: 08961549     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ohc.2005.07.008     Document Type: Review

References (118)

1. B.J. Lipworth Clinical pharmacology of beta 3-adrenoceptors Br J Clin Pharmacol 42 3 1996 291 300
2. C. Weyer, J.F. Gautier, and E. Danforth Jr Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes-an update Diabetes Metab 25 1 1999 11 21
3. I. Kobayashi, T. Ishigami, and S. Umemura Insulin resistance and beta 3-adrenergic receptor function Nippon Rinsho 58 2 2000 333 337
4. M.L. Vuori, and T. Kaila Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients Arch Clin Exp Ophthalmol 233 1995 131 134
5. Physicians' Desk Reference 53 edition 1999 Medical Economics Co. Montvale (NJ) 1741
6. A. Bobik, G.L. Jennings, and P. Asley Timolol pharmacokinetics and effects on heart rate and blood pressure after acute and chronic administration Eur J Clin Pharmacol 16 1979 243 249
7. T.W. Wilson, W.B. Fior, and G.E. Johnson Timolol and propranolol: bioavailability, plasma concentration, and beta blockade Clin Pharmacol Ther 32 1982 676 685
8. A. Shedden, J. Laurence, and R. Tipping Efficacy and tolerability of timolol maleate gel-forming solution versus timolol ophthalmic solution in adults with open angle glaucoma and ocular hypertension: a 6-month, double-masked, multicenter study Clin Ther 23 2001 440 450
9. The MIAMI Trial Research Group Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial Eur Heart J 6 1985 199 226
10. First International Study on Infarct Survival Collaborative Group Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 Lancet 2 1986 823 827
11. J.R. Teerlink, and B.M. Massie Beta-adrenergic blocker mortality trials in congestive heart failure Am J Cardiol 84 1999 R94 R102
12. CIBIS II Investigators and Committees The cardiac insufficiency bisoprolol study II (CIBIS II) Lancet 353 1999 9 13
13. MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF) Lancet 353 1999 2001 2007
14. M. Packer, M.R. Bristow, and J.N. Cohn The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group N Engl J Med 334 1996 1349 1355
15. M. Packer, A.J. Coats, and M.B. Fowler Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658
16. Beta-Blocker Evaluation of Survival Trial Investigators A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure N Engl J Med 344 2001 1659 1667
17. L. Klein, C.M. O'Connor, and W.A. Gattis Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations Am J Cardiol 91 9A 2003 18F 40F
18. A. Hjalmarson Prevention of sudden cardiac death with beta blockers Clin Cardiol 22 Suppl 5 1999 V11 V15
19. M.J. Domanski, H. Krause-Steinrauf, and B.M. Massie A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS J Card Fail 9 5 2003 354 363
20. B.F. McBride, and C.M. White Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET J Clin Pharmacol 45 1 2005 6 24
21. A.C. Finley, B.M. Elliott, and J.J. Robison Prophylactic beta-blocker use to prevent perioperative morbidity and mortality J SC Med Assoc 100 8 2004 223 226
22. M.D. Kertai, E. Boersma, and C.M. Westerhout A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery Eur J Vasc Endovasc Surg 28 4 2004 343 352
23. P.K. Lindenauer, J. Fitzgerald, and N. Hoople The potential preventability of postoperative myocardial infarction: underuse of perioperative beta-adrenergic blockade Arch Intern Med 164 7 2004 762 766
24. T. Glaab, and T. Weiss Use of beta blockers in cardiovascular diseases and bronchial asthma COPD Internist [Berlin] 45 2 2004 221 227
25. J. Chen, M.J. Radford, and Y. Wang Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma J Am Coll Cardiol 37 7 2001 1950 1956
26. M.E. Gutierrez, and A.J. Labovitz Under utilization of beta-adrenoceptor antagonists post-myocardial infarction Am J Cardiovasc Drugs 5 1 2005 23 29
27. S.R. Salpeter, T.M. Ormiston, and E.E. Salpeter Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis Respir Med 97 10 2003 1094 1101
28. S.R. Salpeter, T.M. Ormiston, and E.E. Salpeter Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis Ann Intern Med 137 9 2002 715 725
29. K. Radack, and C. Deck Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials Arch Intern Med 151 9 1991 1769 1776
30. R.J. Kohn Beta-blockers, an important cause of depression: a medical myth without evidence Med Health R I 84 2001 92 95
31. United Kingdom Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes BMJ 317 1998 713 720
32. E.C. Madu, R.C. Reddy, and A.N. Madu Review: the effects of antihypertensive agents on serum lipids Am J Med Sci 312 1996 76 84
33. R. Lakshman, D.J. Reda, and B.J. Materson Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension Arch Intern Med 159 1999 551 558
34. A.L. Coleman, D.L.C. Diehl, and H.D. Jampel Topical timolol decreases plasma high-density lipoprotein cholesterol level Arch Ophthalmol 108 1990 1260 1263
35. W.C. Stewart, H.B. Dubiner, and T.K. Mundorf Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma Am J Ophthalmol 127 1999 142 147
36. S.F. Freedman, N.F. Freedman, and M.B. Shields Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level Am J Ophthalmol 116 1993 600 611
37. D.T. Ko, P.R. Hebert, and C.S. Coffey Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction JAMA 288 3 2002 351 357
38. N.F. Gordon, and J.J. Duncan Effect of beta-blockers on exercise physiology: implications for exercise training Med Sci Sports Exerc 23 1991 668 676
39. L. Vanhees, J.G. Defoor, and D. Schepers Effect of bisoprolol and atenolol on endurance exercise capacity in healthy men J Hypertens 18 2000 35 43
40. K. Dickstein, and T. Aarsland Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men Am J Ophthalmol 121 4 1996 367 371
41. J.S. Friedenwald, and B. Becker Aqueous humor dynamics; theoretical considerations Am J Ophthalmol 41 3 1956 383 398
42. B. Becker Chemical composition of human aqueous humor; effects of acetazolamide Am Med Assoc Arch Ophthalmol 57 6 1957 793 800
43. T.H. Maren The relation between enzyme inhibition and physiologic response in the carbonic anhydrase system J Pharmacol Exp Ther 139 1963 140
44. T. Krupin, W.S. Sly, and M.P. Whyte Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency Am J Ophthalmol 99 4 1985 396 399
45. B.R. Friedland, J. Mallonee, and D.R. Anderson Short-term dose response characteristics of acetazolamide in man Arch Ophthalmol 95 10 1977 1809 1812
46. F.G. Berson, D.L. Epstein, and W.M. Grant Acetazolamide dosage forms in the treatment of glaucoma Arch Ophthalmol 98 6 1980 1051 1054
47. R.A. Stone, T.J. Zimmerman, and D.H. Shin Low-dose methazolamide and intraocular pressure Am J Ophthalmol 83 5 1977 674 679
48. K. Takeda, M. Nakamoto, and C. Yasunaga Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure Clin Nephrol 48 4 1997 266 268
49. D.H. Ellison, M.D. Okusa, and R.W. Schrier Mechanisms of diuretic action R.W. Schrier Diseases of the kidney and urinary tract 7th edition 2001 Lippincott, Williams, Wilkins Philadelphia 2426 2429
50. M.A. Kass, A.E. Kolker, and M. Gordon Acetazolamide and urolithiasis Ophthalmology 88 3 1981 261 265
51. J. Rossert, E. Rondeau, and G. Jondeau Tamm-Horsfall protein accumulation in glomeruli during acetazolamide-induced acute renal failure Am J Nephrol 9 1 1989 56 57
52. E. Elinav, Z. Ackerman, and N.P. Gottehrer Recurrent life-threatening acidosis induced by acetazolamide in a patient with diabetic type IV renal tubular acidosis Ann Emerg Med 40 2 2002 259 260
53. S. De Marchi, and E. Cecchin Severe metabolic acidosis and disturbances of calcium metabolism induced by acetazolamide in patients on haemodialysis Clin Sci [Lond] 78 3 1990 295 302
54. Physician's Desk Reference for Ophthalmology 28th edition 1999 Medical Economics Co. Montvale (NJ)
55. P. Boccardo, G. Remuzzi, and M. Galbusera Platelet dysfunction in renal failure Semin Thromb Hemost 30 5 2004 579 589
56. F.T. Fraunfelder, S.M. Meyer, and G.C. Bagby Jr Hematologic reactions to carbonic anhydrase inhibitors Am J Ophthalmol 100 1 1985 79 81
57. M.H. Schwenk, W.L. St Peter, and M.G. Meese Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysis Pharmacotherapy 15 4 1995 522 527
58. L.F. Roy, L.R. Dufresne, and L. Legault Acetazolamide in hemodialysis patients: a rational use after ocular surgery Am J Kidney Dis 20 6 1992 650 652
59. N.D. Vaziri, J. Saiki, and C.H. Barton Hemodialyzability of acetazolamide South Med J 73 4 1980 422 423
60. J.C. Aronheim Special problems in the geriatric patient J.C. Bennet F. Plum Cecil textbook of medicine 1996 WB Saunders Co. Philadelphia 21 22
61. T.H. Maren, C.W. Conroy, and G.C. Wynns Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor J Ocul Pharmacol Ther 13 1 1997 23 30
62. A.L. Robin The role of alpha-agonists in glaucoma therapy Curr Opin Ophthalmol 8 2 1997 42 49
63. A.L. Robin, and A.L. Coleman Apraclonidine hydrochloride: an evaluation of plasma concentrations and a comparison of its intraocular pressure lowering and cardiovascular effects to timolol maleate Trans Am Ophthalmol Soc 88 1990 149 159
64. G. Walters, and R.H. Taylor Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma Eye 13 Pt 6 1999 797 798
65. R.J. Bowman, J. Cope, and K.K. Nischal Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children Eye 18 1 2004 24 26
66. C.P. Wei, J.A. Anderson, and I. Leopold Ocular absorption and metabolism of topically applied epinephrine and a dipivalyl ester of epinephrine Invest Ophthalmol Vis Sci 17 4 1978 315 321
67. C.R. Kerr, I. Hass, and S.M. Drance Cardiovascular effects of epinephrine and dipivalyl epinephrine applied topically to the eye in patients with glaucoma Br J Ophthalmol 66 2 1982 109 114
68. A.N. Kohn, A.P. Moss, and N.A. Hargett Clinical comparison of dipivalyl epinephrine and epinephrine in the treatment of glaucoma Am J Ophthalmol 87 2 1979 196 201
69. P. Blondeau, and M. Cote Cardiovascular effects of epinephrine and dipivefrin in patients using timolol: a single-dose study Can J Ophthalmol 19 1 1984 29 32
70. T. Palmer Cholinergic agonists A. Goodman Gilman L.S. Goodman A. Gilman Goodman and Gilman's pharmacological basis of therapeutics 6th edition 1980 Macmillan Publishing Co., Inc. New York 90 119
71. S.E. Mayer Neurohumoral transmission and the autonomic nervous system A. Goodman Gilman L.S. Goodman A. Gilman Goodman and Gilman's pharmacological basis of therapeutics 6th edition 1980 Macmillan Publishing Co., Inc. New York 56 91
72. R.G. Hendrickson, A.P. Morocco, and M.I. Greenberg Pilocarpine toxicity and the treatment of xerostomia J Emerg Med 26 4 2004 429 432
73. A.D. Fryer, and O.A. Okanlami Neuronal M2 muscarinic receptor function in guinea-pig lungs is inhibited by indomethacin Am Rev Respir Dis 147 3 1993 559 564
74. A.D. Fryer, and M. Wills-Karp Dysfunction of M2-muscarinic receptors in pulmonary parasympathetic nerves after antigen challenge J Appl Physiol 71 6 1991 2255 2261
75. L. Golkar, K.A. Yarkony, and A.D. Fryer Inhibition of neuronal M(2) muscarinic receptor function in the lungs by extracellular nitric oxide Br J Pharmacol 131 2 2000 312 318
76. E. Bohm, and H. Fabel Changes in lung function following administration of eyedrops containing timolol, metipranolol, pindolol and pilocarpine in healthy probands and patients with mild bronchial asthma Klin Wochenschr [in German] 65 19 1987 920 924
77. H. Kushnick, J.M. Liebmann, and R. Ritch Systemic pilocarpine toxicity from Ocusert leakage Arch Ophthalmol 114 11 1996 1432
78. J.W. Wahl, and G.S. Tyner Echothiophate iodide. The effect of 0.0625 per cent solution on blood cholinesterase Am J Ophthalmol 60 3 1965 419 425
79. A. De Roetth Jr, A. Wong, and W. Dettbarn Blood cholinesterase activity of glaucoma patients treated with phospholine iodide Am J Ophthalmol 62 5 1966 834 838
80. P.E. Hiscox, and C. McCulloch Cardiac arrest occurring in a patient on echothiophate iodide therapy Am J Ophthalmol 60 3 1965 425 427
81. A. Manoguerra, C. Whitney, and R.F. Clark Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops J Toxicol Clin Toxicol 33 5 1995 463 465
82. F. Donati, and D.R. Bevan Controlled succinylcholine infusion in a patient receiving echothiophate eyedrops Can Anaesth Soc J 28 5 1981 488 490
83. P.M. Packman, D.A. Meyer, and R.M. Verdun Hazards of succinylcholine administration during electrotherapy Arch Gen Psychiatry 35 9 1978 1137 1141
84. R.J. Cavallaro, L.W. Krumperman, and F. Kugler Effect of echothiophate therapy on the metabolism of succinylcholine in man Anesth Analg 47 5 1968 570 574
85. T. Gesztes Prolonged apnoea after suxamethonium injection associated with eye drops containing an anticholinesterase agent Br J Anaesth 38 5 1966 408 409
86. E. Mezer, N. Krivoy, and J. Scharf Echothiophate iodide induced transient hyper- and hypothyroidism J Glaucoma 5 3 1996 191 192
87. R.K. Parrish, P. Palmberg, W.P. Sheu XLT Study Group A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study Am J Ophthalmol 135 5 2003 688 703
88. R.N. Weinreb, J.D. Lindsey, and G. Marchenko Prostaglandin FP agonists alter metalloproteinase gene expression in sclera Invest Ophthalmol Vis Sci 45 12 2004 4368 4377
89. J. Hedner, B. Everts, and C.S. Moller Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation Arch Ophthalmol 117 10 1999 1305 1309
90. J. Hedner, N. Svedmyr, and H. Lunde The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma Surv Ophthalmol 41 Suppl 2 1997 S111 S115
91. F.T. Fraunfelder, G.C. Bagby Jr, and D.J. Kelly Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol Am J Ophthalmol 93 3 1982 356 360
92. S. Walker, C.J. Diaper, and R. Bowman Lack of evidence for systemic toxicity following topical chloramphenicol use [review] Eye 12 Pt 5 1998 875 879
93. T. Lancaster, A.M. Swart, and H. Jick Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database BMJ 316 7132 1998 667
94. K. Lahdes, R. Huupponen, and T. Kaila Plasma concentrations and ocular effects of cyclopentolate after ocular application of three formulations Br J Clin Pharmacol 35 5 1993 479 483
95. M. Haaga, T. Kaila, and L. Salminen Systemic and ocular absorption and antagonist activity of topically applied cyclopentolate in man Pharmacol Toxicol 82 1 1998 19 22
96. A.P. Demayo, and M.M. Reidenberg Grand mal seizure in a child 30 minutes after Cyclogyl (cyclopentolate hydrochloride) and 10% Neo-Synephrine (phenylephrine hydrochloride) eye drops were instilled Pediatrics 113 5 2004 E499 E500
97. B.D. Wright Exacerbation of akinetic seizures by atropine eye drops Br J Ophthalmol 76 3 1992 179 180
98. D.A. Fitzgerald, R.M. Hanson, and C. West Seizures associated with 1% cyclopentolate eyedrops J Paediatr Child Health 26 2 1990 106 107
99. J.C. Mwanza Cyclopentolate and grand mal seizure Bull Soc Belge Ophthalmol 273 1999 17 18
100. J.C. Merritt, and E.N. Kraybill Effect of mydriatics on blood pressure in premature infants J Pediatr Ophthalmol Strabis 18 5 1981 42 46
101. J.T. Wilensky, and H.J. Woodward Acute systemic hypertension after conjunctival instillation of phenylephrine hydrochloride Am J Ophthalmol 76 1973 156 157
102. F.T. Fraunfelder, and A.F. Scafidi Possible adverse effects from topical ocular 10% phenylephrine Am J Ophthalmol 85 1978 447 453
103. W.U. McReynolds, W.H. Havener, and J.W. Henderson Hazards of the use of sympathomimetic drugs in ophthalmology Arch Ophthalmol 56 1956 176 179
104. M. Wellwood, and G.V. Goresky Systemic hypertension associated with topical administration of 2.5% phenylephrine HCl Am J Ophthalmol 93 3 1982 369 370
105. V. Kumar, R.D. Schoenwald, and W.A. Barcellos Aqueous versus viscous phenylephrine. I. Systemic absorption and cardiovascular effects Arch Ophthalmol 104 8 1986 1189 1191
106. R.H. Brown, T.S. Wood, and M.G. Lynch Improving the therapeutic index of topical phenylephrine by reducing drop volume Ophthalmology 94 7 1987 847 850
107. M.G. Lynch, R.H. Brown, and S.M. Goode Reduction of phenylephrine drop size in infants achieves equal dilation with decreased systemic absorption Arch Ophthalmol 105 10 1987 1364 1365
108. S.M. Meyer, and F.T. Fraunfelder Phenylephrine hydrochloride Ophthalmology 87 11 1980 1177 1180
109. F. Scotto di Uccio, S. Russo, and A.M. Romano An unusual episode of angina Minerva Cardioangiol [in Italian] 47 3 1999 71 74
110. F.W. Fraunfelder, F.T. Fraunfelder, and B. Jensvold Adverse systemic effects from pledgets of topical ocular phenylephrine 10% Am J Ophthalmol 134 4 2002 624 625
111. K. Shinomiya, M. Kajima, and H. Tajika Renal failure caused by eyedrops containing phenylephrine in a case of retinopathy of prematurity J Med Invest 50 3,4 2003 203 206
112. National Registry of Drug-Induced Ocular Side Effects. Portland OR: Casey Eye Institute, Oregon Health and Science University; 1976-2002
113. J.S. Lustgarten, and S.M. Podos Topical timolol and the nursing mother Arch Ophthalmol 101 9 1983 1381 1382
114. Teratology Society Public Affairs Committee FDA classification of drugs for teratogenic risk Teratology 49 1994 446 447
115. W.F. Hansen, A.E. Peacock, and J. Yankowitz Safe prescribing practices in pregnancy and lactation J Midwifery Womens Health 47 6 2002 409 421
116. American Academy of Pediatrics The transfer of drugs and other chemicals into human milk Pediatr 108 2001 776 789
117. J.F. Friedman Report of the Teratology Society Public Affairs Committee Symposium on FDA Classification of Drugs Teratology 48 1993 5 6
118. M.J. McMahon, and V.L. Katz Clinical teratology J.A. Kuller N.C. Chescheir R.C. Cefalo Prenatal diagnosis and reproductive genetics 1996 Mosby Yearbook, Inc. Baltimore